查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1390468

流感疫苗市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測

Influenza Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

概要

2022年全球流感疫苗市場價值達到62億美元。展望未來， IMARC Group預計到2028年市場規模將達到98億美元，2022-2028年CAGR為7.93%。人們對疫苗接種重要性的認知不斷提高、流感盛行率上升以及政府推動疫苗接種計劃的有利舉措是推動市場的一些主要因素。

流感疫苗，也稱為流感疫苗，是一種預防性醫療產品，旨在提供對流感病毒的保護。它通常透過肌肉注射或鼻噴劑形式施用。該疫苗含有去活化或減弱的流感病毒株，促使免疫系統產生抗體。這些抗體可以幫助身體識別並防禦接觸到的實際病毒，從而降低感染的可能性和症狀的嚴重程度。因此，建議所有年齡層的人都接種流感疫苗，尤其是併發症風險較高的人，例如幼兒、老年人和有潛在健康問題的人。

大眾對疫苗接種在預防流感方面重要性的認知不斷增強，將刺激預測期內市場的成長。隨著人們健康意識的增強以及對免疫接種益處的了解，流感疫苗的使用率顯著上升。此外，流感流行率的上升、季節性爆發和偶爾的流行病促使政府、醫療保健提供者和個人優先考慮接種疫苗作為預防措施，這對市場成長產生了積極影響。除此之外，旨在促進疫苗接種計劃的幾項有利的政府措施和公共衛生運動也促進了市場的成長。此外，許多國家推出疫苗接種活動、補貼疫苗分發和公眾宣傳活動也加快了產品的採用率。此外，人們越來越關注研發（R&D）活動，以開發更有效、保護更廣泛的流感疫苗，這也促進了市場的成長。

流感疫苗市場趨勢/促進因素：

疫苗接種的意識和重要性不斷增強

近年來，大眾對流感疫苗接種重要性的認知顯著提高。健康教育活動、透過各種媒體管道傳播訊息以及醫療保健組織的努力極大地促進了這種意識的提高。隨著人們健康意識的增強並了解免疫接種的好處，對流感疫苗的需求大幅上升。現在人們認知到，及時接種疫苗可以保護他們免於感染流感，並有助於防止流感傳播給弱勢群體。這種意識的提高導致社會對疫苗接種的態度發生轉變，促使更多的人尋求並優先考慮流感疫苗接種作為一項重要的預防措施。

季節性流感爆發和流行病不斷增加

季節性流感爆發的周期性發生，加上流感大流行的偶爾出現，仍然是推動市場成長的主要因素。每年，季節性流感的爆發都會對醫療保健系統造成沉重負擔，導致住院率和勞動力缺勤率增加。此外，歷史上流感大流行（如 2009 年 H1N1 流感大流行）的破壞性影響更凸顯了採取預防措施的必要性。此類疫情和大流行凸顯了流感病毒帶來的潛在風險，並強調了疫苗接種對於保護個人和社區的重要性，從而推動了對流感疫苗的持續需求。

加大政府支持與舉措

世界各國政府透過各種支持機制和措施在促進流感疫苗接種方面發揮著至關重要的作用。他們擴大投資於疫苗接種活動，以提高人們對流感疫苗重要性的認知，並分配資金來購買和分發疫苗。許多國家為兒童、老年人和醫護人員等優先群體提供補貼或免費疫苗接種，從而提高疫苗的可近性。政府推動的免疫計劃和政策要求在學校或醫療機構等特定環境中接種疫苗，這進一步促進了流感疫苗的接種。政府的廣泛支持為流感疫苗市場的成長創造了有利的環境，並有利於擴大人口覆蓋範圍，保護公眾健康並減輕流感相關疾病的負擔。

流感疫苗產業細分：

IMARC Group提供了全球流感疫苗市場報告各細分市場主要趨勢的分析，以及 2023-2028 年全球、區域和國家層面的預測。我們的報告根據疫苗類型、技術、年齡層和給藥途徑對市場進行了分類。

依疫苗類型細分：

四價

三價

四價代表最受歡迎的流感疫苗類型

該報告根據疫苗類型對市場進行了詳細的細分和分析。這包括四價和三價。根據該報告，四價代表了最大的細分市場。

四價疫苗類型可增強對多種流感病毒株的保護。與針對三種流感株（兩種甲型流感株和一種乙型流感株）的傳統三價疫苗不同，四價疫苗還包含一種額外的乙型流感株。這種擴大覆蓋範圍至關重要，因為乙型流感病毒經常表現出抗原漂移，導致三價疫苗可能無法充分涵蓋的不同譜系的出現。透過提供更廣泛的保護，四價疫苗可以更有效地預防流感感染並減輕疾病負擔。

此外，由於四價疫苗覆蓋範圍廣，醫療保健提供者和個人更喜歡四價疫苗，從而導致更高的需求和細分市場的成長。採用四價疫苗已成為許多疫苗接種計劃的標準，鼓勵製造商對其生產和分銷進行投資，以滿足全球對更有效和更全面的流感疫苗接種日益成長的需求。

按技術分類：

以雞蛋為主

基於細胞的

蛋類佔市場最大佔有率

報告還提供了基於該技術的詳細市場細分和分析。這包括基於雞蛋和基於細胞的。報告稱，以雞蛋為主的食品佔據了最大的市場。

以雞蛋為基礎的技術是用於疫苗生產的常規方法之一，其中流感病毒株在雞蛋中生長，然後收穫並加工用於疫苗製劑。儘管替代疫苗生產技術已廣泛使用，但基於雞蛋的方法由於其既定的安全性、可擴展性和成本效益而被廣泛使用。許多領先的製造商擁有廣泛的雞蛋生產能力，使他們能夠生產大量疫苗，以滿足流感季節和疫情爆發期間的全球需求。

此外，隨著對更具創新性和更快的疫苗生產的需求不斷成長，製造商正在探索更新的技術，例如基於細胞和重組的方法。然而，基於雞蛋的技術的傳統繼續推動該細分市場的成長，特別是在其仍然是主要生產方法的地區，確保全球流感疫苗的穩定供應。

按年齡層別分類：

兒科

成人

兒科佔據市場主導地位

報告還提供了基於年齡層的詳細市場細分和分析。這包括兒童和成人。報告顯示，兒科佔據了最大的市場佔有率。

兒科領域是流感疫苗市場的重要驅動力，因為它在保護嬰幼兒免受流感和減少其在社區內傳播方面發揮著至關重要的作用。兒童，尤其是五歲以下的兒童，更容易出現嚴重的流感相關併發症，因此疫苗接種對於保障他們的健康至關重要。兒童疫苗經過專門配製，可在年輕接種者中引發強烈的免疫反應，確保充分預防疾病。

此外，給兒童接種疫苗有助於建立群體免疫力，減少病毒向老年人和免疫系統受損的人等弱勢群體的傳播。因此，醫療保健提供者、政府和家長認知到兒童流感疫苗接種的重要性，導致對兒童流感疫苗的需求增加，從而推動了這一領域的成長。製造商不斷創新並生產安全有效的兒科疫苗，有助於改善公共衛生結果並減輕流感的整體負擔。

依給藥途徑分類：

注射

鼻噴劑

報告還根據給藥途徑對市場進行了詳細的細分和分析。這包括注射和鼻噴劑。

注射劑和鼻噴劑的選擇在滿足個人喜好和需求方面發揮著至關重要的作用。雖然注射仍然是最廣泛使用和首選的疫苗接種方法，但鼻噴劑提供了一種無針替代方案，尤其對兒童和有針恐懼症的個人有吸引力。這種雙重方法提高了疫苗的整體接受度和使用率，有助於提高不同年齡層的疫苗接種率。

此外，鼻噴劑提供了一種更方便、更有效的疫苗輸送方式，使醫療保健提供者能夠在大規模疫苗接種活動或社區環境中更快速地接種疫苗。因此，注射劑和鼻噴劑的選擇進一步擴大了疫苗接種的可及性並使疫苗接種選擇多樣化，從而確保了流感疫苗的更廣泛覆蓋範圍。因此，製造商正在大力投資這兩種交付方法，並認知到它們在促進公共衛生和遏制流感影響方面的重要性。

按地區分類：

北美洲

美國

加拿大

亞太

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美在市場上表現出明顯的主導地位

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（英國、德國、法國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美佔據最大的市場佔有率。

北美佔據了最大的市場佔有率，因為該地區擁有完善的醫療基礎設施、高額醫療支出和先進的研究能力，為疫苗開發和分銷創造了有利的環境。此外，該地區經歷了季節性流感負擔，促使醫療當局優先考慮疫苗接種計劃和運動。此外，積極主動的政府舉措，例如公眾宣傳活動和補貼疫苗分發，有助於增加整個北美的疫苗接種率。

另一個主要貢獻因素是人們對預防性醫療保健的日益重視以及人們對流感疫苗接種益處的認知不斷提高。如今，製造商認知到北美市場的潛力，並正在投資研究和生產設施，以滿足該地區的需求。

競爭格局：

隨著製造商積極尋求創新策略以提高疫苗功效、可近性和便利性，市場正在穩定成長。此外，更先進和具有廣泛保護性的疫苗的開發正在推動市場成長。各個主要參與者正在增加與研究相關的努力，以創造能夠更好地預防多種流感病毒株的疫苗，減少頻繁更新的需要並提高整體有效性。此外，疫苗生產技術的進步，例如基於細胞和重組技術，使得生產速度更快、規模更大，確保了季節性需求激增和潛在疫情期間的穩定供應。此外，人們正在努力改進疫苗輸送方法，開發無針疫苗，包括皮內或鼻噴疫苗。此類創新有助於解決疫苗猶豫問題並促進更廣泛的疫苗接種涵蓋範圍，從而加強對抗流感及其對全球公共衛生的影響。我們也預期市場將出現新進業者、主要參與者之間加強合作以及持續的產品創新，以推動流感疫苗產業內的健康競爭。

該報告對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。市場上的一些主要參與者包括：

雅培實驗室

阿斯特捷利康公司

中超有限公司

第一三共株式會社

緊急生物解決方案公司

F.霍夫曼-拉羅氏股份公司

伽瑪疫苗有限公司

葛蘭素史克公司

默克公司

諾華公司

輝瑞公司

賽諾菲

科興

最近的發展：

2021 年 2 月，葛蘭素史克擴大了與 Vir Biotechnology 的合作，標誌著應對流感預防和治療全球挑戰的策略性舉措。此次合作旨在開發單株抗體，這是一種可以特異性中和流感病毒的標靶療法。單株抗體在針對病毒感染提供預防（預防）和治療（治療）益處方面顯示出巨大的潛力。

2022年9月，輝瑞公司啟動了以mRNA為基礎的流感疫苗的第3期臨床研究。該候選疫苗採用改良 RNA 技術，該技術在其他疫苗（包括基於 mRNA 的 COVID-19 疫苗）中顯示出了巨大的前景。該研究招募了 25,000 名 18 歲及以上的美國成年人，反映了試驗的廣泛範圍和疫苗的潛在目標族群。透過涵蓋大量參與者，該試驗旨在收集有關疫苗安全性、有效性、免疫原性（觸發免疫反應的能力）和耐受性的可靠資料。

2021 年 9 月，賽諾菲收購了臨床階段 mRNA 治療公司 Translate Bio，用於開發新型季節性流感疫苗。此次收購符合該公司致力於推進創新醫療保健解決方案並增強其在 mRNA 治療領域能力的承諾。透過將 Translate Bio 的專業知識和資源涵蓋旗下，賽諾菲獲得了最先進的 mRNA 疫苗平台和研究管道，這可以顯著加速下一代流感疫苗的開發。

本報告回答的關鍵問題

  • 2022年全球流感疫苗市場規模是多少
  • 2023-2028年全球流感疫苗市場預計成長率是多少
  • 推動全球流感疫苗市場的關鍵因素是什麼
  • 推動全球流感疫苗市場的關鍵因素是什麼
  • COVID-19 對全球流感疫苗市場有何影響
  • 根據疫苗類型，全球流感疫苗市場的細分如何
  • 基於技術的全球流感疫苗市場區隔如何
  • 全球流感疫苗市場依年齡層分類是怎樣的
  • 全球流感疫苗市場的重點區域有哪些
  • 10. 全球流感疫苗市場的主要參與者/公司有哪些？

本報告回答的關鍵問題

  • 2022年全球流感疫苗市場規模有多大？
  • 2023-2028年全球流感疫苗市場的預期成長率是多少？
  • 推動全球流感疫苗市場的關鍵因素是什麼？
  • 推動全球流感疫苗市場的關鍵因素是什麼？
  • COVID-19 對全球流感疫苗市場有何影響？
  • 根據疫苗類型，全球流感疫苗市場的詳細情形如何？
  • 基於科技的全球流感疫苗市場區隔如何？
  • 全球流感疫苗市場依年齡層分類是怎樣的？
  • 全球流感疫苗市場的重點區域有哪些？
  • 全球流感疫苗市場的主要參與者/公司有哪些？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球流感疫苗市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：按疫苗類型分類的市場區隔

  • 四價
    • 市場走向
    • 市場預測
  • 三價
    • 市場走向
    • 市場預測

第 7 章：依科技分類的市場

  • 以雞蛋為主
    • 市場走向
    • 市場預測
  • 基於細胞的
    • 市場走向
    • 市場預測

第 8 章：按年齡層別分類的市場區隔

  • 兒科
    • 市場走向
    • 市場預測
  • 成人
    • 市場走向
    • 市場預測

第 9 章：按管理途徑分類的市場

  • 注射
    • 市場走向
    • 市場預測
  • 鼻噴劑
    • 市場走向
    • 市場預測

第 10 章：按地區分類的市場細分

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • AstraZeneca plc
    • CSL Limited
    • Daiichi Sankyo Company Limited
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche AG
    • Gamma Vaccines Pty Ltd
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • SINOVAC
Product Code: SR112023A4206

Abstract

The global influenza vaccine market reached a value of US$ 6.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.8 Billion by 2028, exhibiting a CAGR of 7.93% during 2022-2028. The increasing awareness about the importance of vaccination, rising prevalence of influenza, and favorable government initiatives promoting vaccination programs are some of the major factors propelling the market.

An influenza vaccine, also known as a flu vaccine, is a preventive medical product designed to provide protection against influenza viruses. It is typically administered through an injection into the muscle or as a nasal spray. The vaccine contains inactivated or weakened strains of the influenza virus, prompting the immune system to produce antibodies. These antibodies help the body recognize and defend against the actual virus if exposed, reducing the likelihood of infection and the severity of symptoms. As a result, influenza vaccine is recommended for individuals of all ages, especially those at higher risk of complications, such as young children, elderly individuals, and people with underlying health conditions.

The increasing awareness among the masses about the significance of vaccination in preventing influenza will stimulate the growth of the market during the forecast period. As people become more health-conscious and educated about the benefits of immunization, the uptake of influenza vaccines has risen significantly. Moreover, the rising prevalence of influenza, seasonal outbreaks, and occasional pandemics are prompting governments, healthcare providers, and individuals to prioritize vaccination as a preventive measure, which is positively influencing the market growth. Apart from this, several favorable government initiatives and public health campaigns aimed at promoting vaccination programs has catalyzed the market growth. Additionally, the introduction of vaccination drives, subsidized vaccine distribution, and public awareness campaigns across numerous countries has accelerated the product adoption rate. Furthermore, the increasing focus on research and development (R&D) activities to develop more effective and broadly protective influenza vaccines is contributing to the market growth.

Influenza Vaccine Market Trends/Drivers:

Growing awareness and importance of vaccination

In recent years, there has been a notable increase in public awareness about the importance of influenza vaccination. Health education campaigns, information dissemination through various media channels, and efforts by healthcare organizations have significantly contributed to this growing awareness. As people become more health-conscious and informed about the benefits of immunization, the demand for influenza vaccines has risen substantially. Individuals now recognize that timely vaccinations can protect them from contracting the flu as well as help prevent its spread to vulnerable populations. This heightened awareness has led to a shift in societal attitudes toward vaccination, driving more people to seek and prioritize flu vaccination as a crucial preventive measure.

Rising seasonal influenza outbreaks and pandemics

The cyclical occurrence of seasonal influenza outbreaks, coupled with the occasional emergence of influenza pandemics, continues to be a major factor propelling the market growth. Each year, seasonal flu outbreaks result in a significant burden on healthcare systems, with increased hospitalization rates and workforce absenteeism. Moreover, the devastating impact of historical influenza pandemics, like the H1N1 pandemic in 2009, has reinforced the need for preventive measures. Such outbreaks and pandemics highlight the potential risks posed by the influenza virus and underscore the importance of vaccination to protect individuals and communities, driving sustained demand for influenza vaccines.

Increasing government support and initiatives

Governments worldwide play a crucial role in promoting influenza vaccination through various support mechanisms and initiatives. They are increasingly investing in vaccination campaigns to raise awareness about the importance of flu shots and allocating funds to procure and distribute vaccines. Many countries offer subsidized or free vaccination for priority groups, such as children, elderly individuals, and healthcare workers, thereby improving vaccine accessibility. Government-driven immunization programs and policies mandate vaccination in certain settings, such as schools or healthcare facilities, further contributing to influenza vaccine uptake. This extensive governmental support creates a conducive environment for the growth of the influenza vaccine market and facilitates broader population coverage, protecting public health and reducing the burden of influenza-related illnesses.

Influenza Vaccine Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global influenza vaccine market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on vaccine type, technology, age group and route of administration.

Breakup by Vaccine Type:

Quadrivalent

Trivalent

Quadrivalent represents the most popular type of influenza vaccine

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes quadrivalent and trivalent. According to the report, quadrivalent represented the largest segment.

The quadrivalent vaccine type offers enhanced protection against multiple influenza strains. Unlike the traditional trivalent vaccines, which target three flu strains (two influenza A strains and one influenza B strain), the quadrivalent vaccine includes an additional influenza B strain. This expanded coverage is crucial as influenza B viruses often exhibit antigenic drift, leading to the emergence of distinct lineages that may not be adequately covered by trivalent vaccines. By offering broader protection, quadrivalent vaccines are more effective in preventing influenza infections and reducing the burden of the disease.

Furthermore, healthcare providers and individuals are preferring quadrivalent vaccines owing to their comprehensive coverage, leading to a higher demand and segment growth. The adoption of quadrivalent vaccines has become a standard in many vaccination programs, encouraging manufacturers to invest in their production and distribution to meet the rising global demand for more effective and comprehensive influenza vaccination.

Breakup by Technology:

Egg-based

Cell-based

Egg-based holds the largest share in the market

A detailed breakup and analysis of the market based on the technology has also been provided in the report. This includes egg-based and cell-based. According to the report, egg-based accounted for the largest market share.

Egg-based technology is one of the conventional methods used for vaccine production, wherein the influenza virus strains are grown in chicken eggs before being harvested and processed for vaccine formulation. Despite the widespread availability of alternative vaccine production technologies, the egg-based method has been widely utilized due to its established safety, scalability, and cost-effectiveness. Many leading manufacturers have extensive egg-based production capabilities, allowing them to produce large quantities of vaccines to meet global demand during flu seasons and pandemic outbreaks.

Moreover, as the demand for more innovative and faster vaccine production grows, manufacturers are exploring newer technologies such as cell-based and recombinant approaches. However, the legacy of egg-based technology continues to drive the segment growth, particularly in regions where it remains the predominant production method, ensuring a stable supply of influenza vaccines worldwide.

Breakup by Age Group:

Pediatric

Adult

Pediatric dominates the market

A detailed breakup and analysis of the market based on the age group has also been provided in the report. This includes pediatric and adult. According to the report, pediatric accounted for the largest market share.

The pediatric segment is a significant driver of the market for influenza vaccine due to its vital role in protecting infants and young children from influenza and reducing its spread within communities. Children, especially those under the age of five, are more susceptible to severe flu-related complications, making vaccination crucial in safeguarding their health. Pediatric vaccines are specifically formulated to elicit a robust immune response in young recipients, ensuring adequate protection against the disease.

Moreover, vaccinating children helps create herd immunity, reducing the transmission of the virus to vulnerable populations, such as the elderly and individuals with compromised immune systems. As a result, healthcare providers, governments, and parents recognize the importance of pediatric influenza vaccination, leading to a higher demand for pediatric flu vaccines, thus fueling the growth of this segment. Manufacturers continue to innovate and produce safe and effective pediatric vaccines, contributing to better public health outcomes and reducing the overall burden of influenza.

Breakup by Route of Administration:

Injection

Nasal Spray

A detailed breakup and analysis of the market based on the route of administration has also been provided in the report. This includes injection and nasal spray.

The availability of both injection and nasal spray options plays a crucial role in catering to individual preferences and needs. While the injection remains the most widely used and preferred method for vaccine administration, the nasal spray provides a needle-free alternative, especially appealing to children and individuals with needle phobia. This dual approach increases overall vaccine acceptance and uptake, contributing to higher vaccination rates across different age groups.

Additionally, the nasal spray offers a more convenient and efficient mode of vaccine delivery, enabling healthcare providers to administer vaccines more rapidly during large-scale vaccination campaigns or in community settings. As a result, the availability of both injection and nasal spray options further expands accessibility and diversifies vaccination choices, ensuring broader coverage for influenza vaccines. Therefore, manufacturers are heavily investing in both delivery methods, recognizing their importance in promoting public health and curbing the impact of influenza.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (the United Kingdom, Germany, France, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a well-established healthcare infrastructure, high healthcare expenditure, and advanced research capabilities that foster a conducive environment for vaccine development and distribution. Moreover, the region experiences a seasonal burden of influenza, prompting healthcare authorities to prioritize vaccination programs and campaigns. In addition, proactive government initiatives, such as public awareness campaigns and subsidized vaccine distribution, contribute to increased vaccine uptake across North America.

Another major contributing aspect is the growing emphasis on preventive healthcare and the increasing awareness among the population about the benefits of influenza vaccination. Manufacturers today recognize the potential of the North American market and are investing in research and production facilities to cater to the region's needs.

Competitive Landscape:

The market is experiencing steady growth as manufacturers are actively pursuing innovative strategies to enhance vaccine efficacy, accessibility, and convenience. Moreover, the development of more advanced and broadly protective vaccines is driving the market toward growth. Various key players are increasing their research-related efforts to create vaccines that offer better protection against multiple influenza strains, reducing the need for frequent updates and improving overall effectiveness. Additionally, advancements in vaccine production techniques, such as cell-based and recombinant technologies, have enabled faster and more scalable manufacturing, ensuring a steady supply during seasonal demand surges and potential pandemics. Moreover, efforts are being made to improve vaccine delivery methods, with the development of needle-free options, including intradermal or nasal spray vaccines. Such innovations help address vaccine hesitancy and facilitate broader vaccination coverage, thus strengthening the fight against influenza and its impact on global public health. We also expect the market to witness new entrants, increased partnerships among key players, and continual product innovations to drive healthy competition within the influenza vaccine industry.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

AstraZeneca plc

CSL Limited

Daiichi Sankyo Company Limited

Emergent BioSolutions Inc.

F. Hoffmann-La Roche AG

Gamma Vaccines Pty Ltd

GlaxoSmithKline plc

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Sanofi

SINOVAC

Recent Developments:

In February 2021, GlaxoSmithKline plc expanded its collaboration with Vir Biotechnology, signifying a strategic move to address the global challenge of influenza prevention and treatment. This collaboration aims to develop monoclonal antibodies, a type of targeted therapy that can specifically neutralize the influenza virus. Monoclonal antibodies have shown promising potential in providing both prophylactic (preventive) and therapeutic (treatment) benefits against viral infections.

In September 2022, Pfizer Inc. initiated the phase 3 clinical study for mRNA-based influenza vaccine. This vaccine candidate utilizes modified RNA technology, which has shown great promise in other vaccines, including the mRNA-based COVID-19 vaccines. The study enrolled 25,000 U.S. adults aged 18 years and older, reflecting the broad scope of the trial and the potential target population for the vaccine. By including a substantial number of participants, the trial aims to gather robust data on the vaccine's safety, efficacy, immunogenicity (ability to trigger an immune response), and tolerability.

In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company, for the development of new and seasonal vaccines for influenza. The acquisition aligns with the company's commitment to advancing innovative healthcare solutions and enhancing its capabilities in the field of mRNA-based therapeutics. By bringing Translate Bio's expertise and resources under its umbrella, Sanofi has gained access to cutting-edge mRNA vaccine platforms and research pipelines, which can significantly accelerate the development of next-generation influenza vaccines.

Key Questions Answered in This Report

  • 1. What was the size of the global influenza vaccine market in 2022?
  • 2. What is the expected growth rate of the global influenza vaccine market during 2023-2028?
  • 3. What are the key factors driving the global influenza vaccine market?
  • 4. What are the key factors driving the global influenza vaccine market?
  • 5. What has been the impact of COVID-19 on the global influenza vaccine market?
  • 6. What is the breakup of the global influenza vaccine market based on the vaccine type?
  • 7. What is the breakup of the global influenza vaccine market based on the technology?
  • 8. What is the breakup of the global influenza vaccine market based on the age group?
  • 9. What are the key regions in the global influenza vaccine market?
  • 10. Who are the key players/companies in the global influenza vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Influenza Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Quadrivalent
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Trivalent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Egg-based
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cell-based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 Pediatric
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Adult
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Injection
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Nasal Spray
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 AstraZeneca plc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 CSL Limited
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Daiichi Sankyo Company Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emergent BioSolutions Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Gamma Vaccines Pty Ltd
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 GlaxoSmithKline plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Merck & Co. Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Novartis AG
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Pfizer Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sanofi
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 SINOVAC
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials

List of Figures

  • Figure 1: Global: Influenza Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Influenza Vaccine Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Influenza Vaccine Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Influenza Vaccine Market: Breakup by Vaccine Type (in %), 2022
  • Figure 5: Global: Influenza Vaccine Market: Breakup by Technology (in %), 2022
  • Figure 6: Global: Influenza Vaccine Market: Breakup by Age Group (in %), 2022
  • Figure 7: Global: Influenza Vaccine Market: Breakup by Route of Administration (in %), 2022
  • Figure 8: Global: Influenza Vaccine Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Influenza Vaccine (Quadrivalent) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Influenza Vaccine (Quadrivalent) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Influenza Vaccine (Trivalent) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Influenza Vaccine (Trivalent) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Influenza Vaccine (Egg-based) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Influenza Vaccine (Egg-based) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Influenza Vaccine (Cell-based) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Influenza Vaccine (Cell-based) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Influenza Vaccine (Pediatric) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Influenza Vaccine (Pediatric) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Influenza Vaccine (Adult) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Influenza Vaccine (Adult) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Influenza Vaccine (Injection) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Influenza Vaccine (Injection) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Influenza Vaccine (Nasal Spray) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Influenza Vaccine (Nasal Spray) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: North America: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: North America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: United States: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: United States: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Canada: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Canada: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Asia-Pacific: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Asia-Pacific: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: China: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: China: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Japan: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Japan: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: India: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: India: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: South Korea: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: South Korea: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Australia: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Australia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Indonesia: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Indonesia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Europe: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Europe: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Germany: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Germany: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: France: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: France: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: United Kingdom: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: United Kingdom: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Italy: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Italy: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Spain: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Spain: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Russia: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Russia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Latin America: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Latin America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Brazil: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Brazil: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Mexico: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Mexico: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Middle East and Africa: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Middle East and Africa: Influenza Vaccine Market: Breakup by Country (in %), 2022
  • Figure 73: Middle East and Africa: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Global: Influenza Vaccine Industry: SWOT Analysis
  • Figure 75: Global: Influenza Vaccine Industry: Value Chain Analysis
  • Figure 76: Global: Influenza Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Influenza Vaccine Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Influenza Vaccine Market Forecast: Breakup by Vaccine Type (in Million US$), 2023-2028
  • Table 3: Global: Influenza Vaccine Market Forecast: Breakup by Technology (in Million US$), 2023-2028
  • Table 4: Global: Influenza Vaccine Market Forecast: Breakup by Age Group (in Million US$), 2023-2028
  • Table 5: Global: Influenza Vaccine Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 6: Global: Influenza Vaccine Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Influenza Vaccine Market: Competitive Structure
  • Table 8: Global: Influenza Vaccine Market: Key Players